Japan Lifeline (7575) Q3 2025 earnings summary

Executive summary

• 9M FY25 net sales reached ¥42,811M (+11.8% YoY), operating profit ¥9,906M (+17.2%) and net profit ¥7,071M (+14.5%), all record nine-month highs.

• Core product growth and new market expansion offset reimbursement price reductions; full-year earnings and dividend forecasts were raised.

Financial highlights

• 9M gross profit rose 11.2% to ¥25,910M; gross margin was 60.5%, down 30 bps, while operating margin improved 100 bps to 23.1%.

• 9M EPS was ¥99.37, up 23.1% YoY; share repurchases reduced the weighted-average share count.

• One-time SG&A expenses of ¥348M weighed on reported results; excluding them, operating profit rose 21.4% and net profit 20.1% YoY.

• Core product volume growth added ¥2.9bn to profit; reimbursement revisions reduced profit by ¥446M, while lower inventory write-downs added ¥150M.

• Revenue increased ¥4,508M YoY, including ¥3,806M from established segments and ¥934M from strategic growth segments, offset by ¥231M from discontinued businesses.

Outlook and guidance

• FY25 guidance raised to net sales ¥56,800M, operating profit ¥12,600M, net profit ¥9,200M and EPS ¥129.78.

• Dividend forecast increased to ¥53 per share, aligned with a 40% base payout-ratio policy.

• Q4 operating margin projected at 19.3%; higher R&D and other SG&A spending are expected to weigh on sequential margins.

• Q4 has 57 business days versus a 62-day quarterly average for Q1–Q3; five fewer days are expected to reduce revenue by over ¥1bn.

• Q4 SG&A is expected to be ~¥400M higher than prior quarters, including R&D spending exceeding ¥500M in the final three months.